Effect of internal reporting criteria on suspected adverse drug reactions submitted to MedWatch.

The article focuses on the U.S. Food and Drug Administration's (FDA) reliance on voluntarily submitted adverse drug reaction (ADR) reports to assist in identifying postmarketing drug safety issues. MedWatch, the safety information and adverse-event reporting program of the FDA, receives 200,000 to 300,000 reports of suspected ADR annually.